Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

183.08 +1.94 (+1.07%)
Official Closing Price Updated: 7:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
Blue Shield of California Slashes Humira Biosimilar Prices in Landmark Deal
Blue Shield of California partners with Fresenius Kabi and Evio Pharmacy to cut the cost of Humira's biosimilar to $525 per month, with most members paying $0 out of pocket starting January 2025. 
Via Benzinga
Comparing AbbVie With Industry Competitors In Biotechnology Industry
Via Benzinga
Behind the Scenes of AbbVie's Latest Options Trends
Via Benzinga
Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected
Guidance for the second cycle of Medicare drug price negotiations has expectations high for significant savings by 2026. 
Via Benzinga
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
(ABBV) - Analyzing AbbVie's Short Interest
Via Benzinga
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Via Benzinga
Behind the Scenes of AbbVie's Latest Options Trends
Via Benzinga
Spotlight on AbbVie: Analyzing the Surge in Options Activity
Via Benzinga
5 Best Dividend Growth Stocks to Buy in October
These five stocks are known for their generous dividend programs and robust business models. 
Via The Motley Fool
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via Investor Brand Network
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
EQNX::TICKER_START (NYSE:ANVS),(NYSE:LLY),(NYSE:PFE),(NYSE:NVO),(NASDAQ:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Competitor Analysis: Evaluating AbbVie And Competitors In Biotechnology Industry
Via Benzinga
Is ABBVIE INC Ready to Break Out of Its Range?
Interesting Technical Analysis finding for ABBVIE INC (NYSE:ABBV) 
Via Chartmill
Meta, Accenture, Disney And A Major Health Care Stock On CNBC's 'Final Trades'
On CNBC's "Halftime Report Final Trades," Kevin Simpson of Capital Wealth Planning said Meta Platforms is hitting on all cylinders. 
Via Benzinga
15 Best Dividend Stocks for Lifelong Passive Income
These 15 dividend stocks can deliver stable passive income for life. 
Via The Motley Fool
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Bristol Myers' Cobenfy, recently approved by the FDA for schizophrenia, lacks a boxed warning, positioning it as a safer option. Analysts project peak sales of up to $5 billion if approved for... 
Via Benzinga
Exposures Product Safety
AbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its Primary Goal In Patients With Early Disease
AbbVie reports positive Phase 3 results for tavapadon, a once-daily treatment for early-stage Parkinson's disease. The drug showed significant improvements in patient symptoms, meeting primary and... 
Via Benzinga
Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead
Even the mighty Novo Nordisk can't hold a candle to its peer in this area. 
Via The Motley Fool
Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
KarXT, a novel schizophrenia drug, is on the verge of FDA approval, promising to revolutionize treatment. However, access challenges within the US healthcare system could limit its impact on mental... 
Via Benzinga
Exposures Product Safety
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares. 
Via Investor's Business Daily
2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again
For over a decade, these two drugmakers consistently outperformed the benchmark index and could do it again. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Abbie Inc Stocks Elliott Wave Technical Analysis - Wednesday, September 18,
Looking for upside into wave {v} as we are trading within the parallel channel where we could eventually seek for support within wave {iv}. 
Via Talk Markets
TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades'
TransDigm Group (TDG), BJ's Wholesale (BJ), VanEck Semiconductor ETF (SMH), and AbbVie (ABBV) were recommended as top trades on CNBC's Halftime Report. 
Via Benzinga
Topics ETFs
Can AbbVie Regain Its Status As a Top Dividend Growth Stock?
The dividend growth powerhouse is turning the corner. 
Via The Motley Fool
Investing in Biotech or Pharma Stocks? Pay Attention to These 3 Things and You'll Win More
Financial factors aren't the only things that are worth paying attention to. 
Via The Motley Fool
3 Stocks to Buy and Hold Forever
These stocks are built for the long run. 
Via The Motley Fool
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Their dividends are solid. And their businesses are built for the long run. 
Via The Motley Fool
Time To Invest And Or Trade In Bio-Tech Stocks?
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
Is This Company Still a Strong Buy After Tripling the S&P 500's Returns?
The stock has been a winner, but there may be better times ahead for buying. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.